|Bid||90.00 x 900|
|Ask||0.00 x 900|
|Day's Range||91.46 - 99.79|
|52 Week Range||22.01 - 143.79|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021 - May 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||139.20|
Shockwave Medical (NASDAQ: SWAV) posted substantial increases in revenue in the fourth quarter. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com Contributors Brian Orelli and Keith Speights discuss Shockwave's most recent quarter and the opportunities ahead for the medical-device maker. Brian Orelli: Then moving on to Shockwave Medical, which develops treatments to break down calcium deposits in arteries.
Owning small-cap companies can be a little nerve-racking, especially if it's a medical device company that's waiting on FDA approval. For Shockwave Medical (NASDAQ: SWAV) investors, the wait is over. It received the go-ahead from the FDA for its coronary artery disease device this past month.
In this video clip from Motley Fool Live, recorded on Feb. 18, Fool.com contributors Brian Feroldi, Brian Withers, and Matt Frankel, CFP, discuss how to sleep soundly even when your portfolio loses $10,000 over the course of a few days. Matt Frankel: I see a question that I'd really like to address because it's a very important concept.